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Human papillomavirus (HPV) is thought to cause some vulval squamous cell carcinomas (VSCC) by degrading p53 product. Evidence
on whether HPV-negative VSCC results from p53 mutation is conflicting. We performed immunohistochemistry for p53 product on
52 cases of lone vulval intraepithelial neoplasia (VIN), 21 cases of VIN with concurrent VSCC and 67 cases of VSCC. We had
previously performed HPV detection and loss of heterozygosity (LOH) analyses on these samples. Abnormal p53 immunoreactivity
(p53-positive) rates in HPV-positive VSCC and HPV-negative VSCC were 22% (12/54) and 31% (4/13), respectively (Po0.74). p53
immunoreactivity was associated with LOH at the p53 locus (Po0.004), but neither technique differentiated between HPV-positive
and HPV-negative VSCC. p53 immunoreactivity was associated with overall LOH rates (p53-positive VSCC vs p53-negative VSCC
mean fractional regional allelic loss 0.41 vs 0.24, respectively, Po0.027). LOH at 3p25 was more frequent in p53-positive VSCC cf
p53-negative VSCC (70 vs 21%, respectively, Po0.007). There was a trend in p53 disruption associated with invasive disease; HPV-
positive VSCC demonstrated more disruption than VIN associated with VSCC, which had more disruption than lone VIN III (22 vs 10
vs 0%, respectively, Po0.005). In all, three out of 73 cases of VIN were p53-positive. All three were associated with concurrent or
previous VSCC. Meta-analysis of previous studies revealed significantly more p53 disruption in HPV-negative VSCC cf HPV-positive
VSCC (58 vs 33%, respectively; Po0.0001). p53 immunoreactivity/mutation in VIN only appeared in association with VSCC. These
data suggest that HPV-independent vulval carcinogenesis does not exclusively require disruption of p53, p53 disruption may work
synergistically with LOH at specific loci and p53-positive VIN should be checked carefully for the presence of occult invasion.
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The p53 tumour suppressor gene is central to the development of
many solid tumours. It plays key roles in cell cycle regulation and
apoptosis. Oncogenic human papillomavirus (HPV) types are
thought to cause cervical squamous cell carcinoma. The oncogenic
HPV gene products E6 and E7 act on p53 and Rb, respectively. E6
targets p53 product for degradation via the ubiquitin pathway
(Scheffner et al, 1990), while E7 complexes and inactivates Rb
(Dyson et al, 1989). A proportion of vulval squamous cell
carcinoma (VSCC) and the vast majority of vulval intraepithelial
neoplasia (VIN) are associated with oncogenic HPV infection
(Hording et al, 1994; Kohlberger et al, 1998; Rosenthal et al, 2001).
The different patients’ ages (Hording et al, 1994; Monk et al, 1995),
histological subtypes (Hording et al, 1994; Monk et al, 1995) and
the presence of VIN (Hording et al, 1994; Ngan et al, 1999) in
HPV-positive but not HPV-negative VSCC, all support the
hypothesis that VSCC can arise via both an HPV-dependent and
HPV-independent pathway. Few studies have addressed potential
differences in the molecular events in these two groups. Loss of
heterozygosity (LOH) data from ourselves (Rosenthal et al, 2001)
and others (Flowers et al, 1999; Pinto et al, 1999) suggest that
HPV-positive and HPV-negative VSCC consistently undergo loss
of different chromosomal loci. In addition, another study found
differing DNA ploidy in HPV-positive and HPV-negative VSCC
(Scurry et al, 1999).
We hypothesised that as HPV-positive VSCC was likely to
involve p53 dysfunction because of viral E6 gene product, HPV-
negative VSCC might also involve abrogation of the function of
this tumour suppressor gene. Data on p53 in this context are
conflicting. While some studies suggest that p53 mutation is absent
(Kurvinen et al, 1993; Kim et al, 1996) or rare (Lee et al, 1994) in
HPV-positive VSCC, but present in about one-third of HPV-
negative VSCC, other studies, using a variety of techniques,
including immunohistochemistry (IHC), have found 31–48% of
HPV-positive VSCC and 58–75% of HPV-negative VSCC to show
aberrant p53 expression and/or mutation (Milde-Langosch et al,
1995; Pilotti et al, 1995; Kagie et al, 1997a; Flowers et al, 1999;
Ngan et al, 1999). Although all these studies show a trend towards
higher proportions of HPV-negative VSCC exhibiting p53
dysfunction compared with HPV-positive samples, none of these
studies reached statistical significance. We therefore wanted to try
to clarify this issue in a large series and perform a meta-analysis of
all these series.
We also wanted to investigate p53 immunoreactivity as a marker
of progression to invasion. Some studies suggest absent p53
immunoreactivity in lone VIN (Kurvinen et al, 1993; Tervahauta Received 3 October 2002; accepted 9 October 2002
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yet al, 1993; Pilotti et al, 1995; Kohlberger et al, 1998), while others
have found 17–52% p53 immunoreactivity in VIN associated with
VSCC (Milde-Langosch et al, 1995; Kagie et al, 1997a,b; McConnell
et al, 1997; Emanuels et al, 1999). It is therefore possible that p53
immunoreactivity could represent a marker for risk of invasion.
Higher rates of p53 immunoreactivity in VIN from patients with
VSCC compared to those without could indicate a role for this
gene in progression from VIN to VSCC. Finally, because we had
already investigated our samples for LOH at six different
chromosomal loci (Rosenthal et al, 2001), it was possible to
examine any relation between aberrant p53 immunoreactivity and
LOH at specific loci. Here we report the first study of p53 IHC in a
large series of VIN and VSCC samples, also tested for HPV
infection and LOH at multiple chromosomal loci.
MATERIALS AND METHODS
Samples
Patients with VIN and VSCC diagnosed between 1989 and 1997
were identified using the computerised database of the pathology
departments of St Bartholomew’s and the Royal London Hospitals.
Samples obtained were as follows: 43 cases of lone VIN III, four
cases of lone VIN II, five cases of lone VIN I, 49 cases of VSCC and
21 cases of VIN associated with concurrent VSCC. In all, 18 of the
21 cases of VIN associated with concurrent cancer had the VSCC
still remaining on the specimen blocks after serial sectioning.
There were therefore 67 cases of VSCC available for study (18 cases
associated with concurrent VIN and 49 cases not associated with
VIN). Of the 21 cases of VIN associated with VSCC, 18 were VIN
III, two were VIN II and one was VIN I. Of the 67 VSCC cases, 24
were stage I, 11 were stage II, nine were stage III, three were stage
IV, and in 20 information for accurate staging was not available
because specimens were biopsies only. The relevant paraffin-
embedded tissue samples were serially sectioned as follows: one
4-mm section was mounted, stained with haematoxylin and eosin,
covered and used as a reference slide. One 4-mm section was used
for p53 IHC.
LOH analyses and HPV DNA detection and typing
The methods used for LOH analysis and for detection and typing
of HPV DNA in the samples in this study have been previously
described in detail (Rosenthal et al, 2001). Briefly, DNA was
extracted from microdissected archival normal and neoplastic
vulval tissue. LOH analysis was performed by PCR using
microsatellite markers for the following loci: 17p13–p53, 9p21–
p16, 3p25, 4q21, 5p14 and 11p15. HPV DNA was detected by PCR,
using highly sensitive consensus genital-type HPV L1 gene primers
GP5+ and GP6+ (Kohlberger et al, 1998). PCR products were run
on agarose gels, and amplification bands from samples positive for
HPV DNA were cut out of the gel, and the DNA extracted and
sequenced. The resulting sequences were compared with known
HPV types using a BLAST search.
IHC
Samples were dewaxed in three changes of xylene and rehydrated
in three changes of methanol (100, 90 and 70%). Following
washing in two changes of distilled water, endogenous peroxidase
activity was blocked in 3% H2O2 for 10min. The samples were
washed in two changes of Tris-buffered saline (TBS). Nonspecific
binding was blocked using 1:10 normal goat serum (Dako, Ely,
UK) in phosphate-buffered saline and 0.1% bovine serum albumin
(PBS–BSA) for 20min in a humidity chamber. Slides were
incubated overnight in 1:50 DO7 anti-p53 mouse monoclonal
antibody (Dako, Ely, UK) in PBS–BSA. This step was omitted for
negative controls. The samples were then incubated for 45min in
1:100 goat anti-mouse secondary biotinylated antibody (Dako,
Ely, UK) in PBS–BSA with 10% normal human serum. The
samples were washed in two changes of TBS and incubated for
45min in 1:200 streptavidin–biotin complex (Dako, Ely, UK) in
TBS. The samples were washed in two changes of TBS. Staining of
primary antibody was performed using the chromagen 3-
diaminobenzidine tetrahydrochloride (DAB) (180mg DAB in
270ml H2O, 30ml TBS, 1ml 0.1 M imidazole and 120ml 30%
H2O2). The slides were counterstained using Mayers Haemalum
(Merck, Poole, UK), washed in water, placed briefly in 1% acid-
alcohol followed by blueing solution (0.5% disodium tetraborate)
and dehydrated in two changes of ethanol. The samples were
placed briefly in xylene to restore refractive index and mounted
using DPX (Merck, Poole, UK). We used a breast cancer sample
known to express p53 as a positive control.
Assessment of p53 staining pattern
Samples were scored as negative (o10% of nuclei positive),
positive (10–50% of nuclei positive) or highly positive (450% of
nuclei positive) (Kagie et al, 1997b). These percentages were
grossly assessed by counting nuclei. All slides were assessed by two
observers (ANR, DH) independently.
Meta-analyses of previous studies of p53 in vulval
neoplasia
Studies were identified using the search terms vulva, vulval
neoplasia, VIN and p53 on PUBMED. References from the
publications retrieved were also obtained. Since a wide variety of
techniques for assessing p53 dysfunction have been used, and not
all studies assessed HPV status, we have made the following
assumptions in combining these results for statistical analysis.
Firstly, all VIN was assumed to be HPV-positive, irrespective of
whether HPV detection was performed. This assumption is
justified by our own data (Rosenthal et al, 2001) and that of
others (Hording et al, 1995; Kohlberger et al, 1998), which
indicates that 490% of VIN is HPV-positive. Secondly, 4‘mod-
erate staining’ or 4‘10% of nuclei staining positive’ were taken to
indicate aberrant p53 expression for IHC results, irrespective of
the classification used in the original papers. This was because the
majority of papers used this system. Thirdly, in studies using more
than one method to evaluate p53 dysfunction, ‘aberrant p53’ refers
to the proportion of samples with aberrant p53 by any technique
used in the study, that is, samples showing aberrant p53 with one
technique, but not all techniques, were still counted as aberrant.
While such assumptions may be controversial, they were applied
equally to all studies and to both HPV-positive and HPV-negative
samples (where HPV testing was used), thus minimising bias. In a
rare condition such as VSCC, combining a large number of small
series can reveal important trends, which might otherwise be
missed.
Statistical analysis
Proportions of samples showing p53 immunoreactivity and LOH
were compared using Fisher’s exact test or the w
2 test, where
appropriate. In order to take into account the differing propor-
tions of noninformative cases in the different sample groups, we
calculated the fractional regional allelic loss (FRL) for each sample
(Wistube et al, 1997). FRL for each sample¼total number of loci
undergoing LOH/total number of informative loci. FRL scores for
sample groups were compared using the nonparametric Wilcoxon
test. Meta-analysis of pooled results from previous published series
was performed using the w
2 test. Significance was taken at the 5%
level.
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The median age of patients with HPV-positive VSCC was 67 years
(range 21–94 years) compared with 77 years in the HPV-negative
VSCC patients (range 49–91 years). Only four cases (all HPV-
positive VSCC) exhibited 450% of nuclei staining positive with
DO7. These cases were combined with the samples exhibiting 10–
50% of nuclei staining positive with DO7 to provide the ‘p53-
positive’ group.
The results of p53 staining in the different VIN and VSCC
sample groups are shown in Table 1. Results for LOH at the p53
locus have been published elsewhere (Rosenthal et al, 2001). The
combined IHC and LOH results are shown in Table 2. There was
no significant difference in the proportions of HPV-positive and
HPV-negative VSCC samples demonstrating aberrant p53 by
immunoreactivity either alone (Table 1) or in combination with
LOH (Table 2). There was a significant trend in increasing aberrant
p53 by immunoreactivity either alone (Table 1) or in combination
with LOH (Table 2), going from lone VIN to VIN associated with
VSCC to HPV-positive VSCC. There was a significant correlation
between p53 immunoreactivity and LOH at p53 in VSCC and VIN
(Table 3).
p53 immunoreactivity was significantly associated with overall
rates of LOH (median FRL 0.40 vs 0.25, Po0.027 in p53-positive
VSCC vs p53-negative VSCC). Figure 1 shows the proportions of
p53-positive and p53-negative samples undergoing LOH at six
different chromosomal loci. LOH at 17p13 (p53 locus), 9p21 (p16
locus) and 3p25 was more common in p53-positive VSCC
compared with p53-negative VSCC, but this only reached statistical
significance at 17p13 and 3p25 (57 vs 23%, Po0.028 and 70 vs 21%,
Po0.007, respectively).
The meta-analyses of previous studies of p53 in VSCC and VIN,
along with our own results, are shown in Tables 4 and 5,
respectively. Overall, a significantly higher proportion of HPV-
negative VSCC samples demonstrated aberrant p53 by one or more
methods used, compared with HPV-positive VSCC samples
(Table 4, 33 vs 58%, respectively, Po0.0001). Overall, there was
a significantly higher proportion of aberrant p53 in VIN associated
with VSCC compared with lone VIN (Table 5, 25 vs 7%,
respectively, Po0.0004).
DISCUSSION
We set out to compare the rates of p53 disruption in VIN and
HPV-positive and HPV-negative VSCC in an attempt to establish
whether p53 might be involved in progression from VIN to VSCC,
and whether vulval carcinogenesis in the absence of HPV infection
requires disruption of p53. p53 has been extensively studied in
vulval carcinogenesis. We are aware of 11 studies that have
examined p53 disruption in HPV-typed vulval neoplasia (Kurvinen
et al, 1993; Tervahauta et al, 1993; Lee et al, 1994; Milde-Langosch
et al, 1995; Pilotti et al, 1995; Kim et al, 1996; Kagie et al, 1997a,b;
Kohlberger et al, 1998; Flowers et al, 1999; Ngan et al, 1999). A
further four studies (McConnell et al, 1997; Sliutz et al, 1997;
Emanuels et al, 1999; Scheistren et al, 1999) failed to examine
HPV status, but two of these included VIN samples (McConnell
Table 1 p53 immunoreactivity in VSCC and VIN
p53 immunoreactivity
Sample type Positive n (%) Negative n (%)
HPV-negative VSCC
a 4 (31) 9 (69)
HPV-positive VSCC
a,b 12 (22) 42 (78)
VIN associated with VSCC
b 3 (14) 18 (86)
Lone VIN I, II, III
b 1 (20), 0 (0), 0 (0) 4 (80), 4 (100), 43 (100)
aFisher’s exact test n.s. (Po0.74).
bw
2=10.71, Po0.005.
Table 2 Aberrant p53 (by LOH and/or immunoreactivity) in VSCC and
VIN
Aberrant p53 by LOH and/or
immunoreactivity
Sample type Positive n (%) Negative n (%)
HPV-negative VSCC
a 5 (38) 8 (62)
HPV-positive VSCC
a 18 (33) 36 (66)
VIN associated with VSCC
b 5 (24) 16 (76)
Lone VIN I, II, III
b 1 (20), 0 (0), 5 (12) 4 (80), 4 (100), 38 (88)
aFisher’s exact test n.s. (Po0.76).
bw
2=6.23, Po0.05.
Table 3 Correlation between p53 immunoreactivity and LOH at p53 in
VSCC and VIN
p53 immunoreactivity
LOH at p53 Positive Negative
Loss
a 91 4
Retention
a 86 0
aw
2=8.473, Po0.004.
Note that only 91 out of 140 samples from the IHC results can be included in this
analysis because eight samples lacked normal tissue for comparison with neoplastic
tissue and 41 samples from the LOH analysis were noninformative.
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Figure 1 Proportions of p53-positive and p53-negative samples under-
going LOH at six different chromosomal loci. *Po0.028, **Po0.007.
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British Journal of Cancer (2003) 88(2), 251–256 & 2003 Cancer Research UKet al, 1997; Emanuels et al, 1999). Combining the data from these
studies and our own, it appears that VIN associated with VSCC is
significantly more likely to demonstrate aberrant p53 function
than lone VIN (Table 5, 25 vs 7%, Po0.0004), suggesting that p53
could be a marker to identify women at risk of progression from
VIN to VSCC. In addition, p53 immunoreactivity is only ever
present in VIN when it is associated with cancer. Even the single
case of lone VIN I, which demonstrated abnormal p53 immuno-
reactivity in our study, came from a women who had invasive VSCC
4 years previously. However, only approximately 25% of VIN
associated with VSCC demonstrated aberrant p53 function in the
meta-analysis. While this proportion is too low to predict which
women with VIN will develop VSCC, it does suggest that any
women with VIN staining positive for p53 should be carefully
assessed to exclude invasion.
In our series, aberrant p53 (by IHC or LOH and IHC combined)
was more frequent in HPV-positive VSCC than in the associated
VIN, which in turn had more aberrant p53 than lone VIN,
suggesting that p53 might be involved in progression to invasive
disease. This is surprising when one considers the probable
aetiology of VIN. In cervical neoplasia, HPV E6 and E7
oncoproteins inhibit cell cycle arrest and apoptosis, allowing the
proliferation of mutant clones. The almost universal presence of
oncogenic HPV types in VIN and VIN-associated VSCC (Beck-
mann et al, 1991; Hording et al, 1995; Van Beurden et al, 1995;
Rosenthal et al, 2001), along with the fact that HPV infection is
associated with transcription of E6 and E7 in VIN III (Higgins et al,
1991; Jochmus et al, 1993; Van Beurden et al, 1995) and VSCC
(Higgins et al, 1991; Park et al, 1991), suggests that HPV can also
induce some cases of VSCC in a manner analogous to its effects in
the cervix. If oncogenic HPV precipitates the accumulation of
mutations throughout the genome in vulval neoplasia, then p53
mutations may occur. As mutant p53 has a longer half-life than
wild type, allowing its recognition by the DO7 antibody, it may be
that p53 immunoreactivity in VIN and VSCC may simply be an
index of the mutation burden of the tissue. This would also explain
our finding of nearly double the FRL in p53-positive VSCC
compared with p53-negative VSCC (median FRL 0.40 vs 0.25,
respectively, Po0.027).
We found a significant association between LOH at p53 and p53
immunoreactivity (Table 3, Po0.004). However, despite this
correlation, LOH at p53 frequently occurred in the absence of
p53 immunoreactivity. This is not surprising, as LOH does not
prove that the retained allele is mutated. p53-positive VSCC
underwent LOH at 3p25 significantly more often than p53-negative
VSCC (Figure 1, 70 vs 21%, Po0.007), suggesting that LOH at this
Table 4 Studies of p53 in VSCC
Study
No. of VSCC
samples
Technique for
HPV/p53 detection
Proportion of
HPV-positive VSCC
with aberrant p53 (%)
Proportion of
HPV-negative VSCC
with aberrant p53 (%)
Tervahauta et al (1993), Kurvinen et al (1993) 6 CP+RE+ISH/IHC+SSCP+Seq 2/5 (40) 1/1 (100)
Lee et al (1994) 21 SB+CP+TSP/SSCP +Seq 1/12 (8) 4/9 (44)
Pilotti et al (1995) 23 ISH+SB/IHC+SSCP+Seq 4/11 (36) 8/12 (75)
Milde-Langosch et al (1995) 40 CP+TSP/IHC+TGGE+Seq 5/11 (46) 19/29 (66)
Kim et al (1996) 18 CP+Seq+SB/Seq 0/7 (0) 4/11 (36)
Kagie et al (1997b) 66 CP+Seq/IHC 4/12 (33) 31/54 (58)
Pinto et al (1999) 12
a CP+RFLP+TSP/LOH 3/7 (43) 4/5 (80)
Flowers et al (1999) 29
b CP+TSP/LOH+SSCP+Seq 4/14 (29) 9/15 (60)
Ngan et al (1999) 48 CP+TSP+SB/IHC+SSCP+Seq 11/23 (48) 16/25 (64)
Present study 67 CP+Seq/LOH+IHC 18/54 (33) 5/13 (38)
Total 330 – 52/156 (33)* 101/174 (58)*
aA total of 16 cases, but four are noninformative.
bIn all, 30 cases, but one case is both noninformative and with no mutation.
*Po0.0001.
CP=consensus primers, IHC=immunohistochemistry, ISH=in situ hybridisation, RE=restriction enzyme digestion, RFLP=restriction fragment length polymorphism, Seq=DNA
sequencing, SB=Southern blotting, SSCP=single stranded conformational polymorphism analysis, TSP=type-specific primers, TGGE=temperature gel gradient electrophoresis.
Table 5 Studies of p53 in VIN
Study
No. and type of
VIN samples
Technique for
HPV/p53 detection
Proportion of VIN
with aberrant p53 (%)
Kurvinen et al (1993), Tervahauta et al (1993) 2 lone VIN CP+RE+ISH/IHC+SSCP+Seq 0/2 (0)
Pilotti et al (1995) 6 lone VIN ISH+SB/IHC+SSCP+Seq 0/6 (0)
Milde-Langosch et al (1995) 12 VIN associated with VSCC CP+TSP/IHC+TGGE+Seq 4/12 (33)
Kagie et al (1997a) 60 VIN associated with VSCC CP+Seq/IHC 10/60 (17)
McConnell et al (1997) 33 VIN associated with VSCC Not performed/IHC 17/33 (52)
Kohlberger et al 1998 28 lone VIN CP/IHC 0/28 (0)
Emanuels et al 1999 14 VIN associated with VSCC Not performed/IHC 3/14 (21)
Flowers et al 1999 20 VIN associated with VSCC CP+TSP/LOH+SSCP+Seq 1/20 (5)
Present study 21 VIN associated with VSCC, 52 lone VIN CP+Seq/LOH+IHC 5/21 (24) VIN associated with VSCC
6/52 (12) lone VIN
Total for VIN not associated with VSCC (lone VIN) 88 – 6/88 (7)*
Total for VIN associated with VSCC 160 – 40/160 (25)*
* Po0.0004.
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British Journal of Cancer (2003) 88(2), 251–256 & 2003 Cancer Research UKlocus might act synergistically with p53 dysfunction in the
carcinogenic pathway. Interestingly, the Fanconi anaemia com-
plementation group D gene has recently been localised to 3p25.3
(Hejna et al, 2000) and VSCC has been reported in patients with
Fanconi anaemia at ages much younger than is typical of VSCC
(Arnold et al, 1980; Kennedy and Hart, 1982; Wilkinson et al,
1984).
Meta-analysis reveals that HPV-negative VSCC appears to
undergo a significantly increased frequency of p53 disruption
compared with HPV-positive VSCC (Table 4, 58 vs 33%,
Po0.0001), indicating that p53 is involved in the majority of
HPV-negative VSCC. However, our own study and meta-analysis
support the view that p53 disruption is not obligatory in HPV-
independent pathways of vulval carcinogenesis.
In conclusion, we found that p53 immunoreactivity in VIN is
associated with the presence of invasive disease, implying that any
case of VIN staining positive for p53 should be checked carefully
for the presence of occult invasion. Meta-analysis suggests that
HPV-negative VSCC has a significantly greater proportion of
aberrant p53 compared to HPV-positive VSCC; however, nearly
half of all HPV-negative VSCC has no evidence of p53 dysfunction,
thus implicating other molecular events in this pathway. We
observed a significant association between p53 immunoreactivity
and LOH at 3p25 suggesting that a tumour suppressor at this locus
might act synergistically with p53 dysfunction. p53 immuno-
reactivity was also significantly associated with FRL, implicating it
as an index of the mutation burden of the tissue.
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